# TASL

## Overview
TASL, encoded by the CXorf21 gene, is a pivotal adaptor protein involved in the innate immune response, particularly within endolysosomal compartments. It plays a crucial role in the activation of Interferon Regulatory Factor 5 (IRF5) through its interaction with Toll-like receptors (TLRs) 7, 8, and 9, facilitating the transcription of type I interferons and pro-inflammatory cytokines. The protein is characterized by its intrinsically disordered nature, with a structured C-terminal region that includes a conserved pLxIS motif essential for IRF5 activation. TASL's interaction with the lysosomal transporter SLC15A4 is vital for its function, as it undergoes a conformational change to accommodate TASL, thereby modulating immune signaling pathways. Beyond its immune functions, TASL is also implicated in keratinocyte differentiation and skin homeostasis. Its dysregulation is associated with autoimmune diseases such as systemic lupus erythematosus and various cancers, highlighting its significance as a potential therapeutic target (Heinz2020TASL; Park2024TASL; Chen2023Structural).

## Structure
The TASL protein, encoded by the CXorf21 gene, is an intrinsically disordered protein (IDP) with a three-helix bundle arrangement at the C-terminus. This region includes a conserved pLxIS motif, which is crucial for binding and activating IRF5, a key component in the immune response (Custódio2023Molecular; Heinz2020TASL). The N-terminus of TASL is initially disordered but folds into a helical structure upon binding to the peptide/histidine transporter 1 (PHT1). This helical structure comprises the first 34 residues and is essential for the interaction with PHT1, forming a tight binding interface within the central cavity of PHT1's inward-open conformation (Custódio2023Molecular; Custódio2023Moleculara).

The interaction between TASL and SLC15A4 involves the insertion of TASL's N-terminal helix into a cleft in SLC15A4's transmembrane domain, highlighting the structural adaptation required for its function in endolysosomal TLR signaling (Chen2023Structural). The protein's structure and interactions are critical for its role in immune signaling pathways, particularly in the activation of IRF5 by TLR7-9 (Heinz2020TASL).

## Function
TASL (TLR adaptor interacting with endolysosomal SLC15A4) is a crucial adaptor protein involved in the innate immune response. It operates within the endolysosomal compartments of cells, where it interacts with Toll-like receptors (TLRs) 7, 8, and 9. This interaction facilitates the activation of Interferon Regulatory Factor 5 (IRF5), leading to the transcription of type I interferons and pro-inflammatory cytokines, which are essential for the body's defense against pathogens (Heinz2020TASL; Chen2023Structural).

TASL is recruited by the lysosomal transporter SLC15A4, which undergoes a conformational change to form a binding pocket for TASL. This interaction is critical for the regulatory switch in the TLR signaling pathway, highlighting TASL's role in immune signaling (Chen2023Structural). The protein contains a conserved pLxIS motif, which is crucial for its function, as it is involved in the recruitment and activation of IRF5 without affecting other pathways like NF-κB or MAPK (Heinz2020TASL).

In addition to its role in immune signaling, TASL is involved in keratinocyte differentiation by regulating intracellular calcium levels and lysosomal function, which are vital for skin homeostasis and wound healing (Park2024TASL).

## Clinical Significance
Alterations in the TASL gene, which encodes the TLR adaptor interacting with endolysosomal SLC15A4, have been implicated in several diseases, particularly autoimmune conditions and cancers. In the context of systemic lupus erythematosus (SLE), TASL is crucial for the activation of the IRF5 pathway in response to TLR7-9 signaling. Mutations or dysregulation in TASL can impair this pathway, potentially contributing to the pathogenesis of SLE (Xu2024Inhibition; Heinz2020TASL). TASL expression is regulated by the transcription factor STAT3, and its upregulation has been associated with increased inflammation and apoptosis in lupus nephritis, a severe complication of SLE (Xu2024Inhibition).

In cancer, TASL expression varies across different types and is associated with immune infiltration and tumor prognosis. High TASL expression is linked to poor prognosis in low-grade glioma (LGG) but correlates with better outcomes in lung adenocarcinoma (LUAD) and skin cutaneous melanoma (SKCM) (Li2023Pancancer). TASL's role in modulating the tumor microenvironment suggests it could serve as a biomarker for predicting immunotherapy response, particularly in immune 'hot' tumors like SKCM (Li2023Pancancer). These findings highlight TASL's potential as a target for therapeutic intervention in both autoimmune diseases and cancer.

## Interactions
TASL, a protein encoded by the CXorf21 gene, is involved in several critical interactions within the immune signaling pathways. It primarily interacts with the endolysosomal transporter SLC15A4, forming a complex essential for the activation of the transcription factor IRF5 by Toll-like receptors (TLRs) 7, 8, and 9. This interaction is crucial for the transcription of type I interferons and pro-inflammatory cytokines, which are important for antiviral immunity and are implicated in autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (Heinz2020TASL; Chen2023Structural).

TASL is recruited to SLC15A4 through a conformational change in the transporter, which creates a binding pocket for TASL's N-terminal helix. This interaction facilitates the downstream activation of IRF5, leading to its nuclear translocation and subsequent inflammatory response (Chen2023Structural). TASL also interacts with the peptide/histidine transporter 1 (PHT1), where its N-terminal residues bind within the central cavity of PHT1 in its inward-open conformation. This interaction is characterized by a binding affinity of approximately 360 nM and involves key salt bridges and hydrophobic contacts (Custódio2023Molecular). These interactions highlight TASL's role in modulating immune responses through its association with key transporters and signaling proteins.


## References


[1. (Xu2024Inhibition) Jin-Wen Xu, Ming-Yan Wang, Yan Mao, Zheng-Yun Hu, Xiao-Lin Miao, Feng Jiang, and Guo-Ping Zhou. Inhibition of stat3 alleviates lps-induced apoptosis and inflammation in renal tubular epithelial cells by transcriptionally down-regulating tasl. European Journal of Medical Research, January 2024. URL: http://dx.doi.org/10.1186/s40001-023-01610-9, doi:10.1186/s40001-023-01610-9. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s40001-023-01610-9)

[2. (Park2024TASL) Ji Yeong Park, Hyeng-Soo Kim, Hyejin Hyung, Soyeon Jang, Jiwon Ko, Jin Hong Lee, Si-Yong Kim, Song Park, Junkoo Yi, Sijun Park, Su-Geun Lim, Seonggon Kim, Sanggyu Lee, Myoung Ok Kim, Soyoung Jang, and Zae Young Ryoo. Tasl mediates keratinocyte differentiation by regulating intracellular calcium levels and lysosomal function. Scientific Reports, May 2024. URL: http://dx.doi.org/10.1038/s41598-024-61674-3, doi:10.1038/s41598-024-61674-3. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41598-024-61674-3)

[3. (Custódio2023Molecular) Tânia F. Custódio, Maxime Killer, Dingquan Yu, Virginia Puente, Daniel P. Teufel, Alexander Pautsch, Gisela Schnapp, Marc Grundl, Jan Kosinski, and Christian Löw. Molecular basis of tasl recruitment by the peptide/histidine transporter 1, pht1. Nature Communications, September 2023. URL: http://dx.doi.org/10.1038/s41467-023-41420-5, doi:10.1038/s41467-023-41420-5. This article has 7 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-023-41420-5)

[4. (Li2023Pancancer) Huanyu Li, Xiaoyu Sun, Yanyun Zhao, Changzhu Zhang, Kai Jiang, Jie Ren, Lijuan Xing, and Miao He. Pan-cancer analysis of tasl: a novel immune infiltration-related biomarker for tumor prognosis and immunotherapy response prediction. BMC Cancer, June 2023. URL: http://dx.doi.org/10.1186/s12885-023-11015-w, doi:10.1186/s12885-023-11015-w. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12885-023-11015-w)

[5. (Heinz2020TASL) Leonhard X. Heinz, JangEun Lee, Utkarsh Kapoor, Felix Kartnig, Vitaly Sedlyarov, Konstantinos Papakostas, Adrian César-Razquin, Patrick Essletzbichler, Ulrich Goldmann, Adrijana Stefanovic, Johannes W. Bigenzahn, Stefania Scorzoni, Mattia D. Pizzagalli, Ariel Bensimon, André C. Müller, F. James King, Jun Li, Enrico Girardi, M. Lamine Mbow, Charles E. Whitehurst, Manuele Rebsamen, and Giulio Superti-Furga. Tasl is the slc15a4-associated adaptor for irf5 activation by tlr7–9. Nature, 581(7808):316–322, May 2020. URL: http://dx.doi.org/10.1038/s41586-020-2282-0, doi:10.1038/s41586-020-2282-0. This article has 135 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41586-020-2282-0)

[6. (Chen2023Structural) Xudong Chen, Min Xie, Sensen Zhang, Marta Monguió-Tortajada, Jian Yin, Chang Liu, Youqi Zhang, Maeva Delacrétaz, Mingyue Song, Yixue Wang, Lin Dong, Qiang Ding, Boda Zhou, Xiaolin Tian, Haiteng Deng, Lina Xu, Xiaohui Liu, Zi Yang, Qing Chang, Jie Na, Wenwen Zeng, Giulio Superti-Furga, Manuele Rebsamen, and Maojun Yang. Structural basis for recruitment of tasl by slc15a4 in human endolysosomal tlr signaling. Nature Communications, October 2023. URL: http://dx.doi.org/10.1038/s41467-023-42210-9, doi:10.1038/s41467-023-42210-9. This article has 5 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-023-42210-9)

7. (Custódio2023Moleculara) Molecular basis of TASL recruitment by PHT1. This article has 0 citations.